Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 11/20 | 0.51 |
| ▸ | CDK2 | P24941 | 11/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.51 |
| ▸ | CDK4 | P11802 | 6/20 | 0.49 |
| ▸ | CCND3 | P30281 | 6/20 | 0.49 |
| ▸ | GSK3B | P49841 | 5/20 | 0.49 |
| ▸ | PIM1 | P11309 | 4/20 | 0.49 |
| ▸ | MTOR | P42345 | 3/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | CCNK | O75909 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154077 | 0.95 | CCNA2 (0.53) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4164006 | 0.89 | TNK2 (0.48) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4157039 | 0.85 | CDK2 (0.57) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4155605 | 0.85 | TNK2 (0.49) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4154061 | 0.80 | CDK2 (0.59) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4150539 | 0.79 | CDK2 (0.51) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4158608 | 0.74 | CDK2 (0.52) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4169354 | 0.73 | PLK1 (0.53) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL29458796 | 0.72 | CCNA2 (0.59) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL13852037 | 0.71 | SIGMAR1 (0.33) | CCNA2CDK2CCNA1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-01-09 | — | — | US | disclosed |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-05-07 | — | — | US | disclosed |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-07-06 | — | — | US | disclosed |
| US-20170050972-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-02-23 | — | — | US | disclosed |
| US-8541429-B2 | Pyrazolo quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1207/4885CDK2 49/4885CCNA1 933/4885 |
| US-20170050972-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.